These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 8650070

  • 1. Concentration of the endogenous antiandrogen epitestosterone and androgenic C19-steroids in hyperplastic prostatic tissue.
    Hill M, Hampl R, Petrík R, Stárka L.
    Prostate; 1996 Jun; 28(6):347-51. PubMed ID: 8650070
    [Abstract] [Full Text] [Related]

  • 2. The concentrations of the endogenous C19-steroids in hyperplastic prostatic tissue and the effect of finasteride treatment.
    Hill M, Petrik R, Hampl R, Stárka L.
    Horm Metab Res; 1996 Oct; 28(10):562-4. PubMed ID: 8934217
    [Abstract] [Full Text] [Related]

  • 3. [Epitestosterone as an endogenous antiandrogen in men].
    Stárka L, Hill M, Lapcík O, Hampl R.
    Vnitr Lek; 1996 Sep; 42(9):620-3. PubMed ID: 8984769
    [Abstract] [Full Text] [Related]

  • 4. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
    Heracek J, Hampl R, Hill M, Starka L, Sachova J, Kuncova J, Eis V, Urban M, Mandys V.
    Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
    [Abstract] [Full Text] [Related]

  • 5. Methodologic basis for the radioimmunoassay of endogenous steroids in human prostatic tissue.
    Belis JA.
    Invest Urol; 1980 Jan; 17(4):332-6. PubMed ID: 6153177
    [Abstract] [Full Text] [Related]

  • 6. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer.
    Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL.
    Clin Cancer Res; 2005 Jul 01; 11(13):4653-7. PubMed ID: 16000557
    [Abstract] [Full Text] [Related]

  • 7. Epitestosterone in human blood and prostatic tissue.
    Stárka L, Hampl R, Hill M, Lapcík O, Bílek R, Petrik R.
    Eur J Clin Chem Clin Biochem; 1997 Jun 01; 35(6):469-73. PubMed ID: 9228331
    [Abstract] [Full Text] [Related]

  • 8. Steroid content in endometrial tissue.
    Suri NK.
    East Afr Med J; 1997 Apr 01; 74(4):242-8. PubMed ID: 9299827
    [Abstract] [Full Text] [Related]

  • 9. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer.
    Nishiyama T, Hashimoto Y, Takahashi K.
    Clin Cancer Res; 2004 Nov 01; 10(21):7121-6. PubMed ID: 15534082
    [Abstract] [Full Text] [Related]

  • 10. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer.
    Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R.
    Urology; 2008 Oct 01; 72(4):808-12. PubMed ID: 18718641
    [Abstract] [Full Text] [Related]

  • 11. The content of five sex steroids in human testis.
    Zamrazilová L, Sosvorová L, Heráček J, Sobotka V, Hampl R.
    Physiol Res; 2012 Oct 01; 61(2):221-5. PubMed ID: 22292719
    [Abstract] [Full Text] [Related]

  • 12. Effect of aging on endogenous level of 5 alpha-dihydrotestosterone, testosterone, estradiol, and estrone in epithelium and stroma of normal and hyperplastic human prostate.
    Krieg M, Nass R, Tunn S.
    J Clin Endocrinol Metab; 1993 Aug 01; 77(2):375-81. PubMed ID: 7688377
    [Abstract] [Full Text] [Related]

  • 13. Partial filling micellar electrokinetic chromatography analysis of androgens and testosterone derivatives using two sequential pseudostationary phases.
    Amundsen LK, Sirén H.
    J Chromatogr A; 2006 Oct 27; 1131(1-2):267-74. PubMed ID: 16949594
    [Abstract] [Full Text] [Related]

  • 14. Androgen concentrations and their receptors in the periurethral region are higher than those of the subcapsular zone in benign prostatic hyperplasia (BPH).
    Monti S, Di Silverio F, Toscano V, Martini C, Lanzara S, Varasano PA, Sciarra F.
    J Androl; 1998 Oct 27; 19(4):428-33. PubMed ID: 9733145
    [Abstract] [Full Text] [Related]

  • 15. The 11β-hydroxyandrostenedione pathway and C11-oxy C21 backdoor pathway are active in benign prostatic hyperplasia yielding 11keto-testosterone and 11keto-progesterone.
    du Toit T, Swart AC.
    J Steroid Biochem Mol Biol; 2020 Feb 27; 196():105497. PubMed ID: 31626910
    [Abstract] [Full Text] [Related]

  • 16. Correlation between morphometric differences and norepinephrine content in benign prostatic hyperplasia.
    Ishigooka M, Hashimoto T, Hayami S, Suzuki Y, Sasagawa I, Nakada T.
    Prostate; 1996 Jun 27; 28(6):385-91. PubMed ID: 8650076
    [Abstract] [Full Text] [Related]

  • 17. Effects of long-term administration of androgens and estrogen on rhesus monkey prostate: possible induction of benign prostatic hyperplasia.
    Jeyaraj DA, Udayakumar TS, Rajalakshmi M, Pal PC, Sharma RS.
    J Androl; 2000 Jun 27; 21(6):833-41. PubMed ID: 11105909
    [Abstract] [Full Text] [Related]

  • 18. [Measurement of T and DHT contents in normal and diseased human prostate tissues].
    Zhang Y, Ye L, Ding Q, Fang Z, Yao M, Shi D.
    Zhonghua Wai Ke Za Zhi; 2000 Jul 27; 38(7):545-7. PubMed ID: 11832106
    [Abstract] [Full Text] [Related]

  • 19. Comparison of histological compositions and apoptosis in canine spontaneous benign prostatic hyperplasia treated with androgen suppressive agents chlormadinone acetate and finasteride.
    Shibata Y, Fukabori Y, Ito K, Suzuki K, Yamanaka H.
    J Urol; 2001 Jan 27; 165(1):289-93. PubMed ID: 11125427
    [Abstract] [Full Text] [Related]

  • 20. Androgen levels in the plasma and prostatic tissues of patients with benign hypertrophy and carcinoma of the prostate.
    Habib FK, Lee IR, Stitch SR, Smith PH.
    J Endocrinol; 1976 Oct 27; 71(1):99-107. PubMed ID: 62008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.